Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson disease
World Journal of Urology Oct 31, 2019
Yonguc T, Sefik E, Inci I, et al. - In Parkinson disease (PD) patients with overactive bladder (OAB) symptoms, researchers conducted this randomized, double-blind, placebo-controlled study to test short-term effectiveness and safety of fesoterodine fumarate. Sixty-three patients were randomized to receive fesoterodine 4 mg or placebo for 4 weeks from May 2016 to May 2018. Study participants were received fesoterodine fumarate 4 mg daily for another 4 weeks at the open-label extension phase at the end of 4 weeks of randomization phase. In the double-blind phase, the number of micturition episodes per 24 h period significantly improved with the use of fesoterodine fumarate. In the fesoterodine group, the mean number of nocturia and urgency episodes also reduced. According to findings, OAB symptoms in older adults with PD under fesoterodine fumarate treatment have been significantly improved, and this benefit has continued in the short-term open-label portion. Participants' cognitive functions were not impaired by the treatment of fesoterodine 4 mg compared with placebo.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins